Digitalni repozitorij raziskovalnih organizacij Slovenije

Iskanje po repozitoriju
A+ | A- | Pomoč | SLO | ENG

Iskalni niz: išči po
išči po
išči po
išči po

Možnosti:
  Ponastavi


Iskalni niz: "avtor" (Peter Korošec) .

1 - 10 / 45
Na začetekNa prejšnjo stran12345Na naslednjo stranNa konec
1.
Algorithm instance footprint : separating easily solvable and challenging problem instances
Ana Nikolikj, Sašo Džeroski, Mario Andrés Muñoz, Carola Doerr, Peter Korošec, Tome Eftimov, 2023, objavljeni znanstveni prispevek na konferenci

Ključne besede: black-box optimization, algorithms, problem instances, machine learning
Objavljeno v DiRROS: 15.09.2023; Ogledov: 43; Prenosov: 28
.pdf Celotno besedilo (2,03 MB)
Gradivo ima več datotek! Več...

2.
Assessing the generalizability of a performance predictive model
Ana Nikolikj, Gjorgjina Cenikj, Gordana Ispirova, Diederick Vermetten, Ryan Dieter Lang, Andries Petrus Engelbrecht, Carola Doerr, Peter Korošec, Tome Eftimov, 2023, objavljeni znanstveni prispevek na konferenci

Ključne besede: algorithms, predictive models, machine learning
Objavljeno v DiRROS: 15.09.2023; Ogledov: 51; Prenosov: 36
.pdf Celotno besedilo (935,67 KB)
Gradivo ima več datotek! Več...

3.
4.
Vloga radioterapije pri oligometastatskih gastrointestinalnih rakih
Peter Korošec, 2022, objavljeni znanstveni prispevek na konferenci

Povzetek: Zdravljenje s stereotaktično radioterapijo (SBRT) se je v zadnjih letih tudi pri oligometastatskem gastrointestinalnem raku izkazalo za eno izmed pomembnejših možnosti lokalnega ablativnega zdravljenja, ki izboljšuje tako lokalno kontrolo, preživetje brez bolezni, kot tudi celokupno preživetje. Ob tem pa se je stereotaktično obsevanje izkazalo za varno metodo. Glede na lokacijo zasevkov so najpogosteje obsevani zasevki v jetrih in pljučih. Zaradi višje radiorezistentence zasevkov je potrebna večja izsevana doza (BED ≥ 100 Gy). Za čim manj stranskih učinkov pa je potrebna uporaba sistemov, ki zmanjšujejo gibanje tarče in povečujejo natančnost obsevanja. Večina dokazov do sedaj sicer temelji na retrospektivnih analizah in manjših prospektivnih študijah faze I in II. Rezultati prospektivnih študij faze III pa nam bodo v prihodnosti potrdili kdaj in kateri pacienti bodo imeli od zdravljenja z obsevanjem največjo korist.
Ključne besede: gastrointestinalni rak, radioterapija, rak prebavil
Objavljeno v DiRROS: 13.01.2023; Ogledov: 246; Prenosov: 63
.pdf Celotno besedilo (84,10 KB)

5.
Kolorektalni rak
Peter Korošec, 2022, objavljeni strokovni prispevek na konferenci

Ključne besede: oligometastatski raki, onkološki bolniki, obsevanje, sistemsko zdravljenje
Objavljeno v DiRROS: 14.12.2022; Ogledov: 250; Prenosov: 59
.pdf Celotno besedilo (337,56 KB)

6.
Oligometastatski rak
Ivica Ratoša, Karmen Stanič, Tanja Ovčariček, Ajra Šečerov Ermenc, Janka Čarman, Blaž Grošelj, Staša Jelerčič, Peter Korošec, Manja Šešek, Marko Kokalj, Gaber Plavc, Miha Oražem, Helena Barbara Zobec Logar, 2022, pregledni znanstveni članek

Povzetek: Oligometastatska bolezen (OMB) predstavlja vmesno stanje med lokalno napredovalo boleznijo in obsežnejšo metastatsko boleznijo. Zaenkrat ne poznamo specifičnih biomarkerjev, ki bi nam pomagali opredeliti bolnike z majhnim bremenom bolezni, zato diagnoza OMB temelji na slikovni diagnostiki. V zadnjih letih narašča zanimanje za optimizacijo zdravljenja OMB predvsem zaradi obetavnih rezultatov dodatka lokalnega k obstoječemu sistemskemu zdravljenju. S takšnim načinom zdravljenja se je prvič pokazala možnost doseganja dolgotrajnih zazdravitev ali redko celo ozdravitev teh bolnikov. Razlikovanje posameznih vrst OMB in njihovo enotno poimenovanje je pomembno zlasti v kliničnih raziskavah, saj nam omogoča medsebojno primerjavo rezultatov različnih raziskav.
Ključne besede: klasifikacija, oligometastatska bolezen, sistemsko zdravljenje, onkologija
Objavljeno v DiRROS: 06.12.2022; Ogledov: 271; Prenosov: 67
.pdf Celotno besedilo (246,61 KB)

7.
8.
Art v 1 IgE epitopes of patients and humanized mice are conformational
Maja Zabel, Milena Weber, Bernhard Kratzer, Cordula Köhler, Beatrice Jahn-Schmid, Gabriele Gadermaier, Pia Gattinger, Urška Bidovec, Peter Korošec, Ursula Smole, Rudolf Valenta, Winfried F. Pickl, 2022, izvirni znanstveni članek

Povzetek: Background: Worldwide, pollen of the weed mugwort (Artemisia vulgaris) is a major cause of severe respiratory allergy, with its major allergen, Art v 1, being the key pathogenic molecule for millions of patients. Humanized mice transgenic for a human T-cell receptor specific for the major Art v 1 T-cell epitope and the corresponding HLA have been made. Objective: We sought to characterize IgE epitopes of Art v 1–sensitized patients and humanized mice for molecular immunotherapy of mugwort allergy. Methods: Four overlapping peptides incorporating surface-exposed amino acids representing the full-length Art v 1 sequence were synthesized and used to search for IgE reactivity to sequential epitopes. For indirect mapping, peptide-specific rabbit antibodies were raised to block IgE against surface-exposed epitopes on folded Art v 1. IgE reactivity and basophil activation studies were performed in clinically defined mugwort-allergic patients. Secondary structure of recombinant (r) Art v 1 and peptides was determined by circular dichroism spectroscopy. Results: Mugwort-allergic patients and humanized mice sensitized by allergen inhalation showed IgE reactivity and/or basophil activation mainly to folded, complete Art v 1 but not to unfolded, sequential peptide epitopes. Blocking of allergic patients’ IgE with peptide-specific rabbit antisera identified a hitherto unknown major conformational IgE binding site in the C-terminal Art v 1 domain. Conclusions: Identification of the new major conformational IgE binding site on Art v 1, which can be blocked with IgG raised against non-IgE reactive Art v 1 peptides, is an important basis for the development of a hypoallergenic peptide vaccine for mugwort allergy.
Ključne besede: mugwort pollen allergy, IgE epitope, allergen-specific immunotherapy
Objavljeno v DiRROS: 31.08.2022; Ogledov: 313; Prenosov: 129
URL Povezava na datoteko

9.
Solid cancer patients achieve adequate immunogenicity and low rate of severe adverse events after SARS-CoV-2 vaccination
Urška Janžič, Urška Bidovec, Katja Mohorčič, Loredana Mrak, Nina Fokter Dovnik, Marija Ivanović, Maja Ravnik, Marina Čakš, Erik Škof, Jerneja Debeljak, Peter Korošec, Matija Rijavec, 2022, izvirni znanstveni članek

Povzetek: Background: SARS-CoV-2 vaccination in cancer patients is crucial to prevent severe COVID-19 disease course. Methods: This study assessed immunogenicity of cancer patients on active treatment receiving mRNA-based SARS-CoV-2 vaccine by detection of anti-SARS-CoV-2 S1 IgG antibodies in serum, before, after the first and second doses and 3 months after a complete primary course of vaccination. Results were compared with healthy controls. Results: Of 112 patients, the seroconversion rate was 96%. A significant reduction in antibody levels was observed 3 months after vaccination in patients receiving immune checkpoint inhibitors versus control participants (p < 0.001). Adverse events were mostly mild. Conclusion: Immunogenicity after mRNA-based vaccine in cancer patients is adequate but influenced by the type of anticancer therapy. Antibody levels decline after 3 months, and thus a third vaccination is warranted.
Ključne besede: onkološko zdravljenje, imunogenost, osnovno cepljenje mRNA, čvrsti tumorji, anticancer treatment, immunogenicity, mRNA-based vaccination, solid cancer
Objavljeno v DiRROS: 24.06.2022; Ogledov: 540; Prenosov: 206
.pdf Celotno besedilo (2,03 MB)

10.
Dynamic contrast-enhanced MRI in malignant pleural mesothelioma : prediction of outcome based on DCE-MRI measurements in patients undergoing cytotoxic chemotherapy
Martina Vivoda Tomšič, Peter Korošec, Viljem Kovač, Sotirios Bisdas, Katarina Šurlan Popović, 2022, izvirni znanstveni članek

Povzetek: The malignant pleural mesothelioma (MPM) response rate to chemotherapy is low. The identification of imaging biomarkers that could help guide the most effective therapy approach for individual patients is highly desirable. Our aim was to investigate the dynamic contrast-enhanced (DCE) MR parameters as predictors for progression-free (PFS) and overall survival (OS) in patients with MPM treated with cisplatin-based chemotherapy. Methods: Thirty-two consecutive patients with MPM were enrolled in this prospective study. Pretreatment and intratreatment DCE-MRI were scheduled in each patient. The DCE parameters were analyzed using the extended Tofts (ET) and the adiabatic approximation tissue homogeneity (AATH) model. Comparison analysis, logistic regression and ROC analysis were used to identify the predictors for the patient's outcome. Results: Patients with higher pretreatment ET and AATH-calculated Ktrans and ve values had longer OS (P≤.006). Patients with a more prominent reduction in ET-calculated Ktrans and kep values during the early phase of chemotherapy had longer PFS (P =.008). No parameter was identified to predict PFS. Pre-treatment ET-calculated Ktrans was found to be an independent predictive marker for longer OS (P=.02) demonstrating the most favourable discrimination performance compared to other DCE parameters with an estimated sensitivity of 89% and specificity of 78% (AUC 0.9, 95% CI 0.74-0.98, cut off > 0.08 min-1). Conclusions: In the present study, higher pre-treatment ET-calculated Ktrans values were associated with longer OS. The results suggest that DCE-MRI might provide additional information for identifying MPM patients that may respond to chemotherapy.
Ključne besede: cisplatin, magnetic resonance imaging, mesothelioma
Objavljeno v DiRROS: 06.04.2022; Ogledov: 740; Prenosov: 342
.pdf Celotno besedilo (1,55 MB)
Gradivo ima več datotek! Več...

Iskanje izvedeno v 0.73 sek.
Na vrh